The stock of Heron Therapeutics Inc (NASDAQ:HRTX) is a huge mover today! About 399,305 shares traded hands. Heron Therapeutics Inc (NASDAQ:HRTX) has declined 8.10% since April 18, 2016 and is downtrending. It has underperformed by 12.53% the S&P500.
The move comes after 8 months negative chart setup for the $735.55M company. It was reported on Nov, 18 by Barchart.com. We have $16.99 PT which if reached, will make NASDAQ:HRTX worth $66.20M less.
Heron Therapeutics Inc (NASDAQ:HRTX) Ratings Coverage
Out of 7 analysts covering Heron Therapeutics (NASDAQ:HRTX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Heron Therapeutics has been the topic of 11 analyst reports since August 3, 2015 according to StockzIntelligence Inc. Jefferies maintained it with “Buy” rating and $58 target price in Wednesday, September 23 report. As per Wednesday, September 2, the company rating was initiated by Bank of America. Brean Capital maintained Heron Therapeutics Inc (NASDAQ:HRTX) rating on Monday, August 10. Brean Capital has “Buy” rating and $45 price target. The firm has “Buy” rating given on Monday, August 3 by Brean Capital. The stock of Heron Therapeutics Inc (NASDAQ:HRTX) has “Outperform” rating given on Wednesday, September 23 by Leerink Swann. Lake Street initiated the shares of HRTX in a report on Thursday, December 10 with “Buy” rating. Aegis Capital initiated the shares of HRTX in a report on Wednesday, October 26 with “Buy” rating.
According to Zacks Investment Research, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA.”
Another recent and important Heron Therapeutics Inc (NASDAQ:HRTX) news was published by Nasdaq.com which published an article titled: “Oversold Conditions For Heron Therapeutics” on October 03, 2016.
HRTX Company Profile
Heron Therapeutics, Inc., incorporated on February 5, 1987, is a biotechnology company. The Firm is engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology (Biochronomer technology), which can deliver therapeutic levels of a range of otherwise short-acting pharmacological agents over a period of days to weeks with a single subcutaneous injection.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.